Skip to content

Study · Case report or series · n = 1 · 2009

8 results

Teriparatide treatment in adult hypophosphatasia in a patient exposed to bisphosphonate: a case report.

Doshi KB, Hamrahian AH, Licata AA

Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases1 Sept 2009Cited by 31 (Europe PMC)

PMID22461258 (opens in a new tab)PMCIDPMC2811362 (opens in a new tab)PepBankPUB-22461258
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, fracture site pain improved after teriparatide compared with baseline.

    In plain wordsIn a woman with hypophosphatasia, teriparatide reduced fracture site pain compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFracture site pain
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    20 mcg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Daily teriparatide injections, 20 mcg subcutaneously were prescribed.At 8-weeks follow-up, fracture site pain, weight-bearing and non weight-bearing pain improved significantly allowing ambulation for prolonged periods without assistance.
    1 context sentence
    Summary · context
    We describe the case of a woman with hypophosphatasia previously exposed to bisphosphonate and subsequently treated with teriparatide (recombinant human PTH 1-34).
  2. 02HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, weight-bearing pain improved after teriparatide compared with baseline.

    In plain wordsIn a woman with hypophosphatasia, teriparatide reduced pain during weight bearing compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseWeight-bearing pain
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    20 mcg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Daily teriparatide injections, 20 mcg subcutaneously were prescribed.At 8-weeks follow-up, fracture site pain, weight-bearing and non weight-bearing pain improved significantly allowing ambulation for prolonged periods without assistance.
    1 context sentence
    Summary · context
    We describe the case of a woman with hypophosphatasia previously exposed to bisphosphonate and subsequently treated with teriparatide (recombinant human PTH 1-34).
  3. 03HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, non-weight-bearing pain improved after teriparatide compared with baseline.

    In plain wordsIn a woman with hypophosphatasia, teriparatide reduced pain without weight bearing compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseNon-weight-bearing pain
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    20 mcg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Daily teriparatide injections, 20 mcg subcutaneously were prescribed.At 8-weeks follow-up, fracture site pain, weight-bearing and non weight-bearing pain improved significantly allowing ambulation for prolonged periods without assistance.
    1 context sentence
    Summary · context
    We describe the case of a woman with hypophosphatasia previously exposed to bisphosphonate and subsequently treated with teriparatide (recombinant human PTH 1-34).
  4. 04HumanCase report or seriesEfficacy outcome

    After teriparatide, a woman with hypophosphatasia could walk for prolonged periods without assistance compared with baseline.

    In plain wordsAfter teriparatide, a woman could walk longer without assistance than at baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseUnaided ambulation
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    20 mcg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Daily teriparatide injections, 20 mcg subcutaneously were prescribed.At 8-weeks follow-up, fracture site pain, weight-bearing and non weight-bearing pain improved significantly allowing ambulation for prolonged periods without assistance.
    1 context sentence
    Summary · context
    We describe the case of a woman with hypophosphatasia previously exposed to bisphosphonate and subsequently treated with teriparatide (recombinant human PTH 1-34).
  5. 05HumanCase report or seriesEfficacy outcome

    After teriparatide, a woman with hypophosphatasia slept without discomfort, unlike at presentation.

    In plain wordsAfter teriparatide, a woman slept without discomfort, unlike before treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSleep without discomfort
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Sleep · Sleep
    Studied dose
    20 mcg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    She slept at night without discomfort.
    2 context sentences
    Summary · context
    She could not sleep at night due to discomfort when she moved.
    Summary · context
    We describe the case of a woman with hypophosphatasia previously exposed to bisphosphonate and subsequently treated with teriparatide (recombinant human PTH 1-34).
  6. 06HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, radiographs showed femur fracture healing during teriparatide treatment.

    In plain wordsA woman's femur fractures healed on radiographs during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemur fracture healing
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Radiographs taken at 4 and 16 months of treatment demonstrated healing of femur fractures.
    1 context sentence
    Summary · context
    We describe the case of a woman with hypophosphatasia previously exposed to bisphosphonate and subsequently treated with teriparatide (recombinant human PTH 1-34).
  7. 07HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, urine cross-link-N-telopeptide increased 11% from baseline during teriparatide treatment.

    In plain wordsA woman's urine bone resorption marker increased compared with baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseUrine cross-link-N-telopeptide
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · subcutaneousAs given in this study (human).

    Measurements

    Change in mean urine cross-link N-telopeptide from baseline
    11%
    single patient during teriparatide treatment

    Source sentences

    Summary
    Biochemically, mean urine cross-link-N-telopeptide increased 11% as compared to her base-line, while bone specific alkaline phosphatase did not increase as expected.
    1 context sentence
    Summary · context
    We describe the case of a woman with hypophosphatasia previously exposed to bisphosphonate and subsequently treated with teriparatide (recombinant human PTH 1-34).
  8. 08HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, bone-specific alkaline phosphatase did not increase as expected during teriparatide treatment.

    In plain wordsA woman's bone-specific alkaline phosphatase did not increase as expected during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone-specific alkaline phosphatase
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Biochemically, mean urine cross-link-N-telopeptide increased 11% as compared to her base-line, while bone specific alkaline phosphatase did not increase as expected.
    1 context sentence
    Summary · context
    We describe the case of a woman with hypophosphatasia previously exposed to bisphosphonate and subsequently treated with teriparatide (recombinant human PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.